- Home
- PRPL vs TCRX Comparison
PRPL vs TCRX Comparison
Compare PRPL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRPL | TCRX |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 64.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PRPL | TCRX |
|---|---|---|
| Price | $0.78 | $1.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.00 | ★ $8.50 |
| AVG Volume (30 Days) | 249.9K | ★ 611.9K |
| Earning Date | 11-04-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $457,012,000.00 | $8,423,000.00 |
| Revenue This Year | N/A | $286.83 |
| Revenue Next Year | $12.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.88 |
| 52 Week High | $1.29 | $2.67 |
Technical Indicators
Market Signals| Indicator | PRPL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.77 | 55.62 |
| Support Level | $0.75 | $1.13 |
| Resistance Level | $0.82 | $1.27 |
| Average True Range (ATR) | 0.05 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 62.54 | 63.54 |
Price Performance
Historical ComparisonAbout PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.